Literature DB >> 19284065

Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial.

Héctor M García-García1, Nieves Gonzalo, Ravindra Pawar, Neville Kukreja, Dariusz Dudek, Leif Thuesen, John A Ormiston, Evelyn Regar, Patrick W Serruys.   

Abstract

AIMS: The main objective was to use IVUS-backscatter radiofrequency (IVUS-RF) to assess the degradation of a bioabsorbable stent by measuring serial changes in dense calcium (DC) and necrotic core (NC) as assessed by intravascular ultrasound-Virtual Histology (IVUS-VH) and in the strain as assessed by palpography. METHODS AND
RESULTS: In the ABSORB trial, 27 patients treated with a single bioabsorbable everolimus-eluting stent (BVS, Abbott Vascular, Santa Clara, CA, USA) were all imaged with IVUS-RF post-stenting and at 6-month follow-up, and 13 and 12 patients were also investigated pre-stenting with IVUS-VH and palpography respectively. From pre- to post-stenting, with VH (n = 13), there was an increase in mean "DC" (9.8 vs. 25.4%, p = 0.0002) and "NC" (15.5 vs. 30.5%, p = 0.0002). In palpography (n = 12), the mean number of frames with Rotterdam Classification (ROC) III/IV per cm decreased from 1.22 +/- 1.91 to 0.12 +/- 0.31 (p = 0.0781) and the mean cumulative strain values (all frames with ROC I-IV scores) changed from 0.50 +/- 0.27 to 0.20 +/- 0.10% (p = 0.0034). Comparing post-stenting with follow-up (n = 27), VH showed a decrease in "DC" (29.7% vs. 21.1%, p = 0.0001). "NC" also decreased (26.9 vs. 21.5%, p = 0.0027). For palpography (n = 25 patients), an increase in the mean number of frames with ROC III/IV per cm was observed from 0.09 +/- 0.26 to 0.22 +/- 0.36 (p = -0.1563) while the mean cumulative strain values (all frames with ROC I-IV scores) changed from 0.15 +/- 0.10 to 0.26 +/- 0.12% (p < 0.0001).
CONCLUSIONS: IVUS-VH changes at 6 months suggest alteration of the BVS with reduction of RF backscattering by polymeric struts. Strained plaques on the palpograms were almost abolished following stent implantation. However, strain values reappeared within 6 months suggesting an increase in endoluminal deformability of the stented vessel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19284065     DOI: 10.4244/eijv4i4a77

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  18 in total

Review 1.  Applications of grayscale and radiofrequency intravascular ultrasound to image atherosclerotic plaque.

Authors:  Somjot S Brar; Gary S Mintz; Akiko Maehara; Gregg W Stone
Journal:  J Nucl Cardiol       Date:  2010-10       Impact factor: 5.952

2.  Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.

Authors:  Salvatore Brugaletta; Hector M Garcia-Garcia; Scot Garg; Josep Gomez-Lara; Roberto Diletti; Yoshinobu Onuma; Robert Jan van Geuns; Dougal McClean; Dariusz Dudek; Leif Thuesen; Bernard Chevalier; Stephan Windecker; Robert Whitbourn; Cecile Dorange; Karine Miquel-Hebert; Krishnankutty Sudhir; John A Ormiston; Patrick W Serruys
Journal:  Int J Cardiovasc Imaging       Date:  2010-10-13       Impact factor: 2.357

3.  Implications of a bioresorbable vascular scaffold implantation on vessel wall strain of the treated and the adjacent segments.

Authors:  Christos V Bourantas; Hector M Garcia-Garcia; Carlos A M Campos; Yao-Jun Zhang; Takashi Muramatsu; Marie-Angèle Morel; Shimpei Nakatani; Xingyu Gao; Yun-Kyeong Cho; Yuki Isibashi; Frank J H Gijsen; Yoshinobu Onuma; Patrick W Serruys
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-24       Impact factor: 2.357

Review 4.  Assessment of drug-eluting stents and bioresorbable stents by grayscale IVUS and IVUS-based imaging modalities.

Authors:  Salvatore Brugaletta; Jose Ribamar Costa; Hector M Garcia-Garcia
Journal:  Int J Cardiovasc Imaging       Date:  2011-01-30       Impact factor: 2.357

Review 5.  Causes, assessment, and treatment of stent thrombosis--intravascular imaging insights.

Authors:  Daniel S Ong; Ik-Kyung Jang
Journal:  Nat Rev Cardiol       Date:  2015-03-17       Impact factor: 32.419

6.  The Bioresorbable Stent in Perspective-How Much of an Advance is It?

Authors:  Viktor Kočka; Petr Widimský
Journal:  Interv Cardiol       Date:  2014-03

7.  Reproducibility of Shin's method for necrotic core and calcium content in atherosclerotic coronary lesions treated with bioresorbable everolimus-eluting vascular scaffolds using volumetric intravascular ultrasound radiofrequency-based analysis.

Authors:  Eun-Seok Shin; Hector M Garcia-Garcia; Giovanna Sarno; Leif Thuesen; Dariusz Dudek; John A Ormiston; Patrick W Serruys
Journal:  Int J Cardiovasc Imaging       Date:  2011-01-13       Impact factor: 2.357

8.  Assessment of the serial changes of vessel wall contents in atherosclerotic coronary lesion with bioresorbable everolimus-eluting vascular scaffolds using Shin's method: an IVUS study.

Authors:  Eun-Seok Shin; Hector M Garcia-Garcia; Scot Garg; Jurgen Ligthart; Leif Thuesen; Dariusz Dudek; John A Ormiston; Patrick W Serruys
Journal:  Int J Cardiovasc Imaging       Date:  2010-11-16       Impact factor: 2.357

9.  Comparison between treatment of "established" versus complex "off-label" coronary lesions with Absorb® bioresorbable scaffold implantation: results from the GABI-R® registry.

Authors:  Aydin Huseynov; Stefan Baumann; Holger Nef; Thomas Riemer; Steffen Schneider; Thomas Pfannenbecker; Stephan Achenbach; Julinda Mehilli; Thomas Münzel; Tommaso Gori; Jochen Wöhrle; Ralf Zahn; Johannes Kastner; Axel Schmermund; Gert Richardt; Christian W Hamm; Ibrahim Akin
Journal:  Clin Res Cardiol       Date:  2019-06-29       Impact factor: 5.460

10.  First case of stenting of a vulnerable plaque in the SECRITT I trial-the dawn of a new era?

Authors:  Steve Ramcharitar; Nieves Gonzalo; Robert Jan van Geuns; Hector M Garcia-Garcia; Joanna J Wykrzykowska; Jurgen M R Ligthart; Evelyn Regar; Patrick W Serruys
Journal:  Nat Rev Cardiol       Date:  2009-05       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.